Adaptimmune Therapeutics plc (ADAP)
| Market Cap | 246.73M |
| Revenue (ttm) | 18.36M |
| Net Income (ttm) | -163.41M |
| Shares Out | 234.98M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,611,850 |
| Open | 1.080 |
| Previous Close | 1.050 |
| Day's Range | 1.030 - 1.100 |
| 52-Week Range | 0.420 - 2.050 |
| Beta | 2.33 |
| Analysts | Buy |
| Price Target | 4.29 (+308.57%) |
| Earnings Date | Aug 7, 2024 |
About ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreemen... [Read more]
Financial Performance
In 2023, ADAP's revenue was $60.28 million, an increase of 122.05% compared to the previous year's $27.15 million. Losses were -$113.87 million, -31.18% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $4.29, which is an increase of 308.57% from the latest price.
News
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
We are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, m...
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the pote...
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc...
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized ma...
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing in...
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom-...
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell...
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April...
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with c...
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024 Confirmatory evidence for afami-cel full approval agreed wi...
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (...
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers wit...
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for synovial sarcoma in more than a decade Philadelphia, Pennsylvania and O...
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be up to $400 million BLA submitted in 2023 for afami-cel; projecte...
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration Afami-cel data demonstrate better outcomes for people with synovial sarcoma compared to histo...
Adaptimmune Receives Transfer of IND for Lete-cel Program
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma Company will lay out plans for its cell therapy sarcoma fr...
Adaptimmune Reports Third Quarter Financial Results and Business Update
Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission on track to complete in Q4 this year SURPASS Phase 1 tr...
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Candidate is 10x more sensitive to target peptide than competitor candidates Entry into the clinic in 2024 Selection of approaches from next-gen toolbox in development Philadelphia, Pennsylvania and O...
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had clinical responses with lete-cel, by independent review[2]; primary efficacy endpoint requires...
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response of ~12 months (CTOS 2022) Median overall survival (mOS) was ~17 month...
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat cancer, will report fin...
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across a broad range of solid tumors 50% response rate in 26 patients...
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces th...
Adaptimmune Reports Second Quarter Financial Results and Business Update
Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell potency assay - submission now targeted for Q4 2023 Tran...
Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial ...